Scarless Genome Editing of Human Pluripotent Stem Cells via Transient Puromycin Selection

Steyer, B., Q. Bu, E. Cory, K. Jiang, S. Duong, D. Sinha, S. Steltzer, D. Gamm, Q. Chang, and K. Saha. Scarless Genome Editing of Human Pluripotent Stem Cells via Transient Puromycin Selection. Stem Cell Reports, 2018, p. PubMed Text.

Abstract

Genome-edited human pluripotent stem cells (hPSCs) have broad applications in disease modeling, drug discovery, and regenerative medicine. We present and characterize a robust method for rapid, scarless introduction or correction of disease-associated variants in hPSCs using CRISPR/Cas9. Utilizing non-integrated plasmid vectors that express a puromycin N-acetyl-transferase (PAC) gene, whose expression and translation is linked to that of Cas9, we transiently select for cells based on their early levels of Cas9 protein. Under optimized conditions, co-delivery with single-stranded donor DNA enabled isolation of clonal cell populations containing both heterozygous and homozygous precise genome edits in as little as 2 weeks without requiring cell sorting or high-throughput sequencing. Edited cells isolated using this method did not contain any detectable off-target mutations and displayed expected functional phenotypes after directed differentiation. We apply the approach to a variety of genomic loci in five hPSC lines cultured using both feeder and feeder-free conditions.

Keywords: CRISPR/Cas9; disease modeling; genome editing; human pluripotent stem cells; puromycin; scarless; transient selection.